CureVac Profit Margin 2021-2021 | CVAC
Current and historical gross margin, operating margin and net profit margin for CureVac (CVAC) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. CureVac net profit margin as of December 31, 2021 is 0%.
| CureVac Annual Profit Margins |
|---|
| CureVac Quarterly Profit Margins |
|---|
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Biomedical and Genetics | $3.572B | $0.116B |
| CureVac B.V. is a clinical-stage biopharmaceutical company. It engages in developing medicines based on messenger ribonucleic acid. The company's lead clinical programs include CV8102. CureVac B.V. is based in Germany. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bristol Myers Squibb (BMY) | United States | $163.299B | 9.94 |
| Bio-Rad Laboratories (BIO.B) | United States | $15.121B | 32.79 |
| QIAGEN (QGEN) | Netherlands | $10.420B | 16.45 |
| Biohaven Pharmaceutical Holding (BHVN) | United States | $10.085B | 0.00 |
| Ginkgo Bioworks Holdings (DNA) | United States | $4.716B | 0.00 |
| Emergent Biosolutions (EBS) | United States | $1.842B | 7.89 |
| Arcus Biosciences (RCUS) | United States | $1.368B | 34.69 |
| Myovant Sciences (MYOV) | United Kingdom | $0.984B | 0.00 |
| ADC Therapeutics SA (ADCT) | Switzerland | $0.517B | 0.00 |
| Gelesis Holdings (GLS) | United States | $0.358B | 0.00 |
| Zymeworks (ZYME) | Canada | $0.354B | 0.00 |
| Ambrx Biopharma (AMAM) | United States | $0.157B | 0.00 |
| Enzo Biochem (ENZ) | United States | $0.117B | 24.10 |
| SQZ Biotechnologies (SQZ) | United States | $0.095B | 0.00 |
